About Ocata Therapeutics (NASDAQ:OCAT)
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-12.1
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-103.02%
Return on Assets-46.18%
Ocata Therapeutics (NASDAQ:OCAT) Frequently Asked Questions
What is Ocata Therapeutics' stock symbol?
Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."
How were Ocata Therapeutics' earnings last quarter?
Ocata Therapeutics Inc (NASDAQ:OCAT) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter. Ocata Therapeutics had a negative return on equity of 103.02% and a negative net margin of 4,564.66%. View Ocata Therapeutics' Earnings History.
Who are some of Ocata Therapeutics' key competitors?
Some companies that are related to Ocata Therapeutics include Medivation (MDVN), Bioverativ (BIVV), Kite Pharma (KITE), Juno Therapeutics (JUNO), Shire-Nps Pharmaceuticals (NPSP), Auspex Pharmaceuticals (ASPX), Ignyta (RXDX), Clinigen Group (CLIN), Neuroderm (NDRM), Sucampo Pharmaceuticals (SCMP), Raptor Pharmaceutical (RPTP), Cascadian Therapeutics (CASC), Oxford BioMedica (OXB), BioTime (BTX), Biotie Therapies (BITI), Circassia Pharmaceuticals (CIR), MaxCyte (MXCT) and Faron Pharmaceuticals Oy (FARN).
Has Ocata Therapeutics been receiving favorable news coverage?
Press coverage about OCAT stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocata Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Ocata Therapeutics?
Shares of OCAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocata Therapeutics' stock price today?
One share of OCAT stock can currently be purchased for approximately $8.47.
How can I contact Ocata Therapeutics?
Ocata Therapeutics' mailing address is 33 Locke Dr, MARLBOROUGH, MA 01752-1167, United States. The biotechnology company can be reached via phone at +1-508-7561212.
MarketBeat Community Rating for Ocata Therapeutics (OCAT)MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ocata Therapeutics (NASDAQ:OCAT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Ocata Therapeutics (NASDAQ:OCAT) Earnings History and Estimates Chart
Ocata Therapeutics (NASDAQ OCAT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2015||Q3 2015||($0.19)||($0.18)||$0.04 million||$0.08 million||View||N/A|
|5/7/2015||Q1 2015||($0.20)||$0.04 million||View||N/A|
Ocata Therapeutics (NASDAQ:OCAT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com
Ocata Therapeutics (NASDAQ OCAT) Insider Trading and Institutional Ownership History
Ocata Therapeutics (NASDAQ OCAT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/10/2015||Robert Lanza||insider||Sell||35,000||$8.31||$290,850.00||196,509|| |
|7/7/2014||Robert Lanza||Insider||Sell||1,500,000||$0.08||$120,000.00|| |
|1/10/2013||Gary H Rabin||CEO||Sell||12,115,963||$0.12||$1,453,915.56|| |
Ocata Therapeutics (NASDAQ OCAT) News Headlines
Ocata Therapeutics (NASDAQ:OCAT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ocata Therapeutics (NASDAQ:OCAT) Income Statement, Balance Sheet and Cash Flow Statement
Ocata Therapeutics (NASDAQ OCAT) Stock Chart for Friday, March, 23, 2018